Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Strata Critical Medical (SRTA) EBITDA (2019 - 2025)

Historic EBITDA for Strata Critical Medical (SRTA) over the last 7 years, with Q3 2025 value amounting to -$5.6 million.

  • Strata Critical Medical's EBITDA rose 2072.76% to -$5.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$35.5 million, marking a year-over-year increase of 4522.26%. This contributed to the annual value of -$33.9 million for FY2024, which is 5019.45% up from last year.
  • Per Strata Critical Medical's latest filing, its EBITDA stood at -$5.6 million for Q3 2025, which was up 2072.76% from -$5.0 million recorded in Q2 2025.
  • Over the past 5 years, Strata Critical Medical's EBITDA peaked at -$4.2 million during Q1 2021, and registered a low of -$35.6 million during Q4 2023.
  • Over the past 5 years, Strata Critical Medical's median EBITDA value was -$9.9 million (recorded in 2024), while the average stood at -$11.5 million.
  • Per our database at Business Quant, Strata Critical Medical's EBITDA tumbled by 595459.03% in 2021 and then soared by 5922.3% in 2025.
  • Over the past 5 years, Strata Critical Medical's EBITDA (Quarter) stood at -$10.5 million in 2021, then tumbled by 86.77% to -$19.7 million in 2022, then tumbled by 81.08% to -$35.6 million in 2023, then skyrocketed by 51.44% to -$17.3 million in 2024, then surged by 67.51% to -$5.6 million in 2025.
  • Its last three reported values are -$5.6 million in Q3 2025, -$5.0 million for Q2 2025, and -$7.6 million during Q1 2025.